Unified Women's Clinical Research - Greensboro
Welcome,         Profile    Billing    Logout  
 6 Trials 
10 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Anderson, Mark
NCT06329791: A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Active, not recruiting
3
500
US
AZR-MD-001, AZR-MD-001 ophthalmic ointment 0.5%, Vehicle, AZR-MD-001 Vehicle
Azura Ophthalmics, ORA, Inc.
Dry Eye Disease
12/24
11/25
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT03994796: Genetic Testing in Guiding Treatment for Patients with Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/26
06/28
OTC-HOPE, NCT06255782: An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

Recruiting
1/2
13
Europe, US, RoW
ECUR-506
iECURE, Inc.
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
09/26
09/26
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
NCT05100836: SURPASS Impella 5.5 Study

Active, not recruiting
N/A
1017
US
Impella 5.5
Abiomed Inc.
Cardiogenic Shock, Acute Decompensated Heart Failure
03/25
03/25
Anderson
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40

Download Options